Title: Conflict of Interest
1Conflict of Interest Informed Consentfor
Department of Pediatrics Fellows
- Presented by University of Pittsburghs COI
Office - David T. Wehrle, CPA, CIA, CFE/Director
- Khrys X. Myrddin/Associate Director
- July 3, 2008
2What is a Conflict of Interest?
- A potential Conflict of Interest (COI) may exist
if an individuals outside interests (especially
financial) may affect, or perceive to affect,
his/her research, teaching, or administrative
activities at the University.
3Example of Potential Conflict of Interest
- Dr. Karola Kinderschuh developed an orthopedic
device for pediatric patients - The technology is owned by Strait Narrow, Inc.,
in which Dr. Kinderschuh has an ownership
interest - Dr. Kinderschuh is conducting federally sponsored
research to further evaluate the device.
4Why should you care about COI?
- Your COIs can affect
- Your role in studies
- Your potential research subjects willingness to
participate in the research - How your research is viewed by the academic
community and the public.
5Importance of COI Management
- If COI is not managed
- protection of human subjects may be compromised
- integrity of research may be at risk
- the public may lose trust in the University and
its research findings - the investigator/faculty member may lose the
respect of the academic community
6Importance of COI Management contd
- violation of scientific norms may result
- University may lose public support and funding
for academic science - may violate terms of research grants and
contracts (including failure to disclose COI) and
federal regulations. - research results may be excessively delayed or
not published
7Importance of COI Management contd
- there may be a negative impact on students
- University resources may be improperly used
- increased government regulations may result
- scandals or negative media attention may occur.
8COICs Standard COI Management Plan for Human
Subject Research
- University of Pittsburghs primary management
tool is the Conflict of Interest Committees
Standard COI Management Plan for Human Subject
Research (SMP).
9COICs Standard COI Management Plan for Human
Subject Research Details
- I will not serve as Principal Investigator (PI)
on this protocol, although I may serve as a
co-investigator. - I will not be involved in the recruitment of
volunteer subjects, nor will I administer the
informed consent. - I will not engage in the recording of research
data. - I will not be involved in clinical assessments of
study eligibility criteria and intervention
outcomes.
10COICs Standard COI Management Plan for Human
Subject Research Details contd
- I will not participate in data and safety
monitoring activities. - I will not solely be involved in the
interpretation of study results, although I may
be involved as part of a committee that evaluates
study results. Final decisions about the
appropriate interpretation and presentation of
research results shall be the responsibility of
the PI. - The existence of my Significant Financial
Interest will be disclosed in the informed
consent form.
11COICs Standard COI Management Plan for Human
Subject Research Details contd
- If other individuals (such as students, staff, or
other faculty members) will be involved in
research under this protocol, I will notify them
of the existence of my Significant Financial
Interest through the use of a standard
notification form. Students will be engaged in
the protocol only with the approval of their
department chair or dean.
12COICs Standard COI Management Plan for Human
Subject Research Details contd
- I will disclose the existence of my Significant
Financial Interest in any abstracts,
presentations, press releases, or publications
and in any proposals or applications for research
funding related to the nature of that interest. - I will notify the chair of the Conflict of
Interest Committee (Dr. Jerome Rosenberg
jrosenb_at_pitt.edu) of the titles and numbers of
any present or future federal research grants
supporting this protocol.
13Aspects of Informed Consent Requirements
- Clinical aspects of Informed Consent it is a
matter of both ethics and federal regulation that
research subjects - enter a study voluntarily
- be informed about risks and benefits
- understand the difference between experiment and
treatment - understand the information provided.
- COI aspects of Informed Consent consistent with
recommendations of professional organizations and
federal guidance, University policy requires
disclosure of financial COIs as part of the
Standard Management Plan. - Cf. Bramstedt, KA A guide to informed consent
for clinician-investigators Cleveland Clinic
Journal of Medicine 20047111.
http//www.ccjm.org/PDFFILES/Bramstedt11_04.pdf
14Text of Informed Consent in SMP (Example)
- One or more of the investigators conducting this
research has a financial interest in or a patent
for the development of this pediatric heart
valve. This means that it is possible that the
results of this study could lead to personal
profit for the individual investigator(s) and/or
the University of Pittsburgh. This project has
been carefully reviewed to ensure that your
well-being holds more importance than any study
results. Any questions you might have about this
will be answered fully by Dr. Getrude Kleinherz,
412-123-4567, or by the Human Subject Protection
Advocate of the University of Pittsburgh
(866-212-2668).
15Discussion
- Putting yourself in the place of a potential
research subject, what are your thoughts on the
financial disclosure in the Informed Consent
document in terms of - Necessity to disclose
- Your ability to understand it
- The amount of information provided
- Your willingness to be a participant
- ?
16The COINS Study
- Purpose of study analyze aspects of financial
disclosure to potential research participants
provide data and recommendations for the
development of best practices surrounding such
disclosures. - 3-year study
- 5 million of funding
- NIH-sponsored
- Parents of pediatric patients are included in
this study - Conflict of Interest Notification Survey
17COINS Study Views of investigators, et.al.
- Purpose of study to understand the attitudes,
beliefs, and practices of IRB chairs, COIC
chairs, and investigators regarding disclosure of
financial interests to potential research
participants. - The participants included 10 academic medical
centers, 10 independent hospitals, and 10
unaffiliated research entities from which
respondents were recruited. - Weinfurt, KP, Friedman JY, et. al Disclosing
Conflicts of Interest in Clinical Research Views
of Institutional Review Boards, Conflict of
Interest Committees, and Investigators Journal
of Law, Medicine Ethics 2006 34 (3) 581-591.
http//www.pubmedcentral.nih.gov/articlerender.fcg
i?artid1850937
18COINS Study Views of investigators, et.al.
Results
- Most respondents suggested that disclosure should
occur under all circumstances in which a
financial interest exists. - Justifications for such disclosure included
- A participants right to know
- Enabling potential research participants to make
better informed decisions - Engendering participants trust in investigators
and the research institutions - Some respondents underscored the need for
disclosure to prevent a later reaction of
distrust if research participants learned about a
previously undisclosed COI
19COINS Study Views of investigators, et.al.
Results contd
- Some concerns about making disclosures
- Inability of research participants to understand
disclosure - Violation of the investigators privacy
- Possibility that disclosure would affect
potential research participants willingness to
enroll - Possible undermining of the participants trust
in the investigator - Increased length of the Informed Consent document.
20COINS Study Views of investigators, et.al.
Results contd
- Much disagreement about whether the amount of the
financial interest should be disclosed. - None of the investigators thought such detailed
information should be disclosed. - Most respondents seemed to agree that the nature
of the relationship was important to disclose,
but that such disclosures should be kept simple.
21COINS Study Views of Potential Research
Participants
- Purpose of study determine what participants
wanted to know about financial interests, their
capacity to understand the disclosure, and their
reaction to proposed disclosure statement. - Participants 16 focus groups healthy adults,
adults with mild chronic illness, healthy
children, parents of children with leukemia or
brain tumor, adults with heart failure, adults
with cancer. - Weinfurt KP, Friedman JY et al Views of
Potential Research Participants on Conflicts of
Interest Journal of General Internal Medicine
2006 901-906.
22COINS Study Views of Potential Research
Participants Results
- Many participants reported that they did not know
about or hadnt thought about investigators
financial interests in research before
participating in the study. - Participants wanted to know about financial
interest, whether or not those interests would
affect their participation. - Parent of sick child It seems to me, with
this kind of thing, there ought to be disclosure.
Ive never even thought of these kinds of
scenarios until you brought them up hereand its
opened my eyes to the possibilities of things
that can be going on that we have not idea of.
Weve got little folks with lives on the line,
and I think we deserve and ought to know.
23COINS Study Views of Potential Research
Participants Results contd
- Some participants indicated that the COI
disclosure would affect their decision about
participating in research. - Participants felt that disclosure was more
important for riskier studies than for less risky
ones when participants health was at stake,
they suggested that they might be less able to
evaluate the risk posed by a financial
disclosure, even though they generally believe
that such risks are important to consider. - There was variation in subjects ability to
understand the nature implications of financial
interests.
24COINS Study Views of Potential Research
Participants Results contd
- Participants expressed the view that disclosure
of financial interests was important in
preserving trust in doctors/researchers. - Some participants felt the amount of money
received by investigators would be important to
know, whereas other felt they would not want to
know the amount.
25FDA Halts Gene Experiments at University of
Pennsylvania By Rick Weiss and Deborah
NelsonWashington Post Staff WritersSaturday,
January 22, 2000 Page A1 The federal
government yesterday halted all human gene
therapy experiments involving a prominent
researcher at the University of Pennsylvania,
saying an investigation into the September death
of a teenager there found the school's
prestigious program in serious disarray.
26Case of Inadequate COI Disclosure
- Jesse Gelsinger was not informed that several
monkeys injected with the vector had died. - The informed consent document approved by the FDA
was allegedly altered to exclude this
information. - Jesse was also not informed that other humans who
had previously participated in the trial suffered
serious adverse effects.
27Case of Inadequate COI Disclosure contd
- The extent of the PIs and the University of
Pennsylvanias financial COI was not adequately
disclosed to Jesse. - Jesses entry into the trial was deemed reckless,
because his blood ammonia level on the day before
he received the gene transfer exceeded the limit
set forth in the FDA protocol.
28Contact
- Jerome L. Rosenberg, PhD/Chair, COI Committee
- 412-624-3007 jrosenb_at_pitt.edu
- David T. Wehrle, CPA, CIA, CFE/Director, COI
Office - 412-383-1774 wehrledt_at_upmc.edu
- Khrys X. Myrddin/Associate Director, COI Office
- 412-383-2828 myrddink_at_upmc.edu
- Hannelore Rogers, MA/Coordinator, COI Office
- 412-383-1968 rogershn_at_upmc.edu
- COI Web site www.coi.pitt.edu